Ankylosing spondylitis could be treated with immune therapy
Results from a Phase III clinical trial indicate that patients suffering from ankylosing spondylitis could benefit from the biologic drug ixekizumab...
List view / Grid view
Results from a Phase III clinical trial indicate that patients suffering from ankylosing spondylitis could benefit from the biologic drug ixekizumab...
The psoriasis therapeutics market is set to more than double from $6.6 billion in 2014 to over $13.3 billion by 2024, according to research and consulting firm, GlobalData.